Tokyo, 104-0031, Japan
NCT Number: NCT00195585
Study Evaluating Isovorin in Colon Cancer
The purpose of the study is to verify superiority of 1-LV/5FU therapy to UFT Therapy of relapse-free survival time in patients with Dukes C and Cure A colon cancer. Secondary endpoints include disease-free survival time, survival time, and safety.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Dukes C, Cure A colon cancer diagnosed histologically or cytologically
- Normal organ function of bone marrow, heart, liver and kidney
- Age 20-75
Other inclusion applies
Exclusion criteria
- Serious bone marrow suppression, infection, heart disease or complication
- Familial adenomatous polyposis or hereditary nonpolyposis
- Pregnant or breastfeeding women
Other exclusion applies
Treatment and study plan
Isovorin
DrugUFT
DrugPrimary outcomes
-
Relapse-free survival time
Secondary outcomes
-
Disease-free survival time, survival time, safety
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Post-Approved Phase III Study of 1-LV/5FU Therapy
Important dates
- Study start
- 2002
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 19, 2005
- Registry last updated
- Aug 13, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Risk Communication Within Mexican-American Families
NCT00469339
Breast Cancer, Breast Diseases
Houston, Texas, United States
View Trial DetailsMobile Sensor Technologies to Assess General Symptomology of People With Cancer
NCT04465214
Colon Cancer, Colonic Diseases
Bethesda, Maryland, United States
View Trial DetailsCOM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246
Adnexal Diseases, Advanced Cancer
Sarasota, Florida, United States
View Trial DetailsTargeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer
NCT06323421
Colon Cancer, Colonic Diseases
Chicago, Illinois, United States
View Trial Details